Synthesis, antitumor activity and molecular docking study of novel benzofuran-2-yl pyrazole pyrimidine derivatives

Acta Poloniae Pharmaceutica - Drug Research

Volumn 68, Issue 3, 2011, Pages 357-373

  El Zahar, Magdy I ^a   Abd El Karim, Somaia S ^a   Haiba, Mogedda E ^a   Khedr, Mohammed A ^b  

^a NATIONAL RESEARCH CENTRE   (Egypt)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Antitumor activity; Autodock Vina; Benzofuranoyl pyrazoles; Pyrimidin 2 thione; Thiazolidinone; Thymidylate synthase inhibitor; Triazole

Indexed keywords

1 [4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 6 METHYL 2 THIOXOPYRIMIDIN 5 YL]ETHANONE; 2 (2,5 DIOXOPYRROLIDIN 1 YLAMINO) 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,6 DIHYDRO 6 OXOPYRIMIDINE 5 CARBONITRILE; 2 (4 METHOXYBENZYLIDENE) 7 [3 (BENZOFURAN 2 YL)1 PHENYL 1H PYRAZOL 4 YL] 3,5 DIHYDRO 3,5 DIOXO 2H THIAZOLO[3,2 A]PYRIMIDINE 6 CARBONITRILE; 2 [(1H INDOL 3 YL)METHYLENE] 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 3,5 DIHYDRO 3,5 DIOXO 2H THIAZOLO[3,2 A]PYRIMIDINE 6 CARBONITRILE; 2 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 6 HYDRO 4,6 DIOXO 4H PYRIMIDO[2,1 B]BENZO[1,3]OXAZINE 3 CARBONITRILE; 2 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 6 HYDRO 4,6 DIOXO 4H PYRIMIDO[2,1 B]BENZO[1,3]THIAZINE 3 CARBONITRILE; 2 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 6,11 DIHYDRO 4,6 DIOXO 4H PYRIMIDO[2,1 B]QUINAZOLINE 3 CARBONITRILE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,2 DIHYDRO 6 (1,2,3,4 TETRAHYDRONAPHTHALEN 7 YL) 2 IMINOPYRIDINE 3 CARBONITRILE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,2 DIHYDRO 6 (1,2,3,4 TETRAHYDRONAPHTHALEN 7 YL) 2 OXOPYRIDINE 3 CARBONITRILE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,6 DIHYDRO 2 (4,5 DIHYDRO 3 METHYL 5 OXOPYRAZOL 1 YL) 6 OXOPYRIMIDINE 5 CARBONITRILE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,6 DIHYDRO 2 (METHYLTHIO) 6 OXOPYRIMIDINE 5 CARBONITRILE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,6 DIHYDRO 6 OXO 2 (3,5 DIOXOPYRAZOLIDIN 1 YL)PYRIMIDINE 5 CARBONITRILE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 2 HYDRAZINYL 1,6 DIHYDRO 6 OXOPYRIMIDINE 5 CARBONITRILE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 3,4 DIHYDRO 1H INDENO[1,2 D]PYRIMIDINE (5H) THIONINE; 4 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 3,4,5,6,7,8 HEXAHYDROQUINAZOLINE 2 (1H) THIONE; 6 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,2,3,4 TETRAHYDRO 4 OXO 2 THIOXOPYRIMIDINE 5 CARBONITRILE; 6 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 4 CHLORO 1,2 DIHYDRO 2 THIOXOPYRIMIDINE 5 CARBONITRILE; 6 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 4 HYDRAZINYL 1,2 DIHYDRO 2 THIOXOPYRIMIDINE 5 CARBONITRILE; 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,2,3,5 TETRAHYDRO 3,5 DIOXO[1,2,4]TRIAZOLO[4,3 A]PYRIMIDINE 6 CARBONITRILE; 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,2,3,5 TETRAHYDRO 5 OXOIMIDAZO[1,2 A]PYRIMIDINE 6 CARBONITRILE; 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,5 DIHYDRO 3 METHYL 5 OXO[1,2,4]TRIAZOLO[4,3 A]PYRIMIDINE 6 CARBONITRILE; 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 1,5 DIHYDRO 5 OXO [1,2,4]TRIAZOLO[4,3 A]PYRIMIDINE 6 CARBONITRILE; 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 3,5 DIHYDRO 3,5 DIOXO 2 [(THIOPHEN 2 YL)METHYLENE] 2H THIAZOLO[3,2 A]PYRIMIDINE 6 CARBONITRILE; 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 3,5 DIHYDRO 3,5 DIOXO 2H THIAZOLO[3,2 A]PYRIMIDINE 6 CARBONITRILE; 7 [3 (BENZOFURAN 2 YL) 1 PHENYL 1H PYRAZOL 4 YL] 5,6 DIHYDRO 5 THIOXOTETRAZOLO[1,5 F]PYRIMIDINE 8 CARBONITRILE; ANTINEOPLASTIC AGENT; FLUOROURACIL; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CHEMICAL REACTION; CONFORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYCLIZATION; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; LIVER CARCINOMA; MOLECULAR DOCKING; MOLECULAR MODEL; PROTON NUCLEAR MAGNETIC RESONANCE; SUBSTITUTION REACTION;

ANTINEOPLASTIC AGENTS; BENZOFURANS; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEP G2 CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN CONFORMATION; PYRAZOLES; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDYLATE SYNTHASE;

EID: 79956299605     PISSN: 00016837     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kumar R., Nath M., Tyrrell D.L.: J. Med. Chem. 45, 2032 (2002).
2. Deshmukh M.B., Salunkhe S.M., Patil D.R., Anbhule P.V.: Eur. J. Med. Chem. 44, 2651 (2009).
3. Agarwal A., Srivastava K., Puri S.K., Chauhan P.M.S.: Bioorg. Med. Chem. Lett. 15, 3130 (2005).
4. Atwal K.S., Swanson B.N., Unger S.E., Floyd D.M., Moreland S., Hedberg A., O'Reilly B. C.: J. Med. Chem. 34, 806 (1991).
5. Sondhi S.M., Singh N., Johar M., Kumer A.: Bioorg. Med. Chem. 13, 6158 (2005).
6. Noll S., Kralj M., Suman L., Stephan H., Piantanida I.: Eur. J. Med. Chem. 44, 1172 (2009).
7. Longley D.B., Harkin D.P., Johnston P.G.: Nat. Rev. Cancer 3, 330 (2003).
8. Kossakowski J., Ostrowska K., Hejchman E., Wolska I.: Farmaco 60, 519 (2005).
9. Xue Fei Yang, Ling Yi Kong,: Chinese Chem. Lett. 18, 380 (2007).
10. Galal S.A., Abd El-All A.S., Abdellah M.M., El-Diwani H.I.: Bioorg. Med. Chem. Lett. 19, 2420 (2009).
11. Usui T., Seung Ban H., Kawada J., Hirokawab T., Nakamura H.: Bioorg. Med. Chem. Lett. 18, 285 (2008).
12. Yia Y., Fan C.-D., Zhao B.-X., Zhao J, Shin D.-S., Miao J.-Y.: Eur. J. Med. Chem. 43, 2347 (2008).
13. Chan D.C.M., Anderson A.C.: Curr. Med. Chem. 13, 377 (2006).
14. Hawser S., Lociuro S., Islam K.: Biochem. Pharmacol. 71, 94 (2006).
15. Blakley R.L.: Dihydrofolate Reductase. in Folate and Pterines, Blakley R.L., Benkovic S.J., Eds.; vol. 1, p. 191, Wiley, New York 1984.
16. MacKenzie R.E.: Biogenesis and interconversion of substituted tetrahydrofolates. in Folates and Pterines Chemistry and Biochemistry, Blakley R.L., Benkovic S. J. Eds., vol. 1, p. 255, Wiley, New York 1984.
17. Assaraf Y.G.: Cancer Metastasis Rev. 26, 153 (2007).
18. Matherly L.H., Hou Z.: Vitam. Horm. 79, 145 2008).
19. Nikolaos T.: Clin. Cancer Res. 2, 227 (1996).
20. Trott O., Olson A.J.: J. Comput. Chem. 31, 455 (2010).
21. El-Zahar M.I., Abd El-Karim S.S., Anwar M.M.: S. Afr. J. Chem. 62, 189 (2009).
22. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistric D., Warren J.T et al.: J. Natl. Cancer Inst. 82, 1107 (1990).
23. Kamel M.M., El-Zahar M.I., Anwar M.M.: Pakistan J. Sci. Ind. Res. 48, 184 (2005).
24. Amin K.M., El-Zahar M.I., Anwar M.M., Kamel M.M., Mohamed M.H.: Acta Pol. Pharm. Drug Res. 66, 279 (2009).
25. El-Zahar M.I., Abd El-Karim S.S., Haiba M.E.: World J. Chem. 4, 182 (2009).
26. Al-Soud Y.A., Al-Masoudi I.A., Saeed B., Beifuß U., Al-Masoudi N.A.: Chem. Heterocycl. Comp. 42, 583 (2006).
27. Bhat K.S., Poojary B., Prasad D.J., Naik P., Holla B.S.: Eur. J. Med. Chem. 44, 5066 (2009).
28. Park H.-J., Lee K., Park S.-J., Ahn B., Lee J-C., Cho H.Y., LeeK.-I.: Bioorg. Med. Chem. Lett. 15, 3307(2005).
29. Sztanke K., Pasternak K., Rzymowska J., Sztanke M., Kandefer-Szerszen M., et al. Bioorg. Med. Chem. 15, 2837 (2007).
30. Sztanke K., Pasternak K., Rzymowska J., Sztanke M., Kandefer-Szerszen M.: Eur. J. Med. Chem. 43, 1085 (2008).
31. Dilovic I., Rubcic M., Vrdoljak V., Pavelic S. K., Kralj M., Piantanida I., Cindri M. M.: Bioorg. Med. Chem. 16, 5189 (2008).
32. Naik S. D., Ambaye R. Y., Gokhale S. V.: Anticancer Res. 7, 87 (1987).
33. Conchon E., Anizon F., Aboab B., Golsteyn R. M., Leonce S., Pfeiffer B., Prudhomme M.: Eur. J. Med. Chem. 43, 282 (2008). 33.